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A B S T R A C T
Background
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community-acquired lower respiratory tract
infection (LRTI) in children. Pulmonary manifestations are typically tracheobronchitis or pneumonia but M. pneumoniae is also
implicated in wheezing episodes in both asthmatic and non-asthmatic individuals. Although antibiotics are used to treat LRTI, a review
of several major textbooks offers conflicting advice for the use of antibiotics in the management of M. pneumoniae LRTI in children.
Objectives
To determine whether antibiotics are effective in the treatment of childhood LRTI secondary to M. pneumoniae infections acquired in
the community.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2005, issue 1), which contains
the Acute Respiratory Infection Group’s Specialized Register; MEDLINE (1966 to February 2005); and EMBASE (1980 to December
2004).
Selection criteria
Randomised controlled trials comparing antibiotics commonly used for treatingM. pneumoniae (i.e.macrolide, tetracycline or quinolone
classes) versus placebo, or antibiotics from any other class in the treatment of children under 18 years of age with community acquired
LRTI secondary to M. pneumoniae.
Data collection and analysis
The authors independently selected trials for inclusion and assessed methodological quality. Relevant data were extracted and analysed
separately and any disagreements were resolved by consensus.
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Main results
A total of 1352 children were enrolled from six studies. The number of children from one study was unavailable. Data interpretation
was significantly limited by the inability to extract data that specifically referred to children with M. pneumoniae. Clinical response did
not differ between the children randomised to a macrolide antibiotic and the children randomised to a non-macrolide antibiotic. There
were no studies comparing relevant antibiotics with placebo.
Authors’ conclusions
This review found insufficient evidence to draw any conclusions about the efficacy of antibiotics for LRTI secondary to M. pneumoniae
in children. The use of antibiotics forM. pneumoniae LRTI has to be individualised and balanced with possible adverse events associated
with antibiotic use. There is a need for high quality, double-blinded randomised controlled trials to assess the efficacy and safety of
antibiotics for LRTI secondary to M. pneumoniae in children.
P L A I N L A N G U A G E S U M M A R Y
There is insufficient evidence from trials about the benefits of antibiotic treatment for lower respiratory tract infections in
children secondary to Mycoplasma pneumoniae (M. pneumoniae).
M. pneumoniae is an bacterial infection often responsible for lower respiratory tract infections (LRTI) in children. The infection can
present in a number of different ways and themost common respiratory manifestations are acute bronchitis, pneumonia or exacerbation
of asthma. The illness is generally self-limiting with symptoms lasting several weeks. Antibiotics are often given to children with M.
pneumoniae LRTI but the authors found there were no adequate trials which show that antibiotics are effective.
B A C K G R O U N D
Description of the condition
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as
an important cause of community acquired lower respiratory tract
infection (LRTI) in children, accounting for 14% to 34% of cases
(Kogan 2003; Michelow 2004; Nelson 2002; Principi 2002). The
highest attack rates are reported to occur in 5 to 20-year-olds
and the infection is usually self-limiting with symptoms lasting
several weeks (Nelson 2002; Rudolph 2003). More recently M.
pneumoniae has been identified as an important cause of LRTI
in children less than five years of age (Principi 2001). Pulmonary
manifestations are typically tracheobronchitis or pneumonia but
can be complicated by pleural effusion, lung abscess, pneumoth-
orax, bronchiectasis and respiratory distress syndrome (Principi
2002). M. pneumoniae is also implicated in wheezing episodes
in both asthmatic and non-asthmatic individuals (Phelan 1994;
Principi 2001). Extrapulmonary manifestations may include ery-
thema multiforme, myocarditis, encephalitis, Guillain-Barre Syn-
drome, transverse myelitis and haemolytic anaemia (Nelson 2002;
Waites 2003). Radiographic findings are quite variable and non-
diagnostic (Principi 2001). In some cases there can be significant
radiological changes in the absence of clinical signs on auscultation
of the chest (so-called ’walking pneumonia’) (Rudolph 2003).
Description of the intervention
Antibiotics are frequently used to treat LRTI and empiric antibi-
otic therapy is often chosen to cover both bacteria and atypical or-
ganisms (Kogan 2003). A review of several major textbooks offers
conflicting advice for management of M. pneumoniae LRTI. The
chapter on M. pneumoniae in a paediatric respiratory textbook
(Phelan 1994) mentions that there is little evidence of beneficial
effect from antibiotic therapy. This is in contrast to the recommen-
dations in a major general paediatric textbook (Rudolph 2003)
andpaediatric infectious disease textbook (Katz 1998)which states
that erythromycin is the treatment of choice.
Why it is important to do this review
The conclusion that antibiotics are effective in M. pneumoniae
chest infections seems to have been drawn from trials of antibiotic
therapy for community acquired or atypical pneumonia, where
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M. pneumoniae was identified as a causative organism in a sub-
group of cases. In these studies, macrolide antibiotics, to which M.
pneumoniae is susceptible, have been compared to non-macrolide
antibiotics. However, it is not always possible to draw meaningful
conclusions from the results, as the numbers of individuals with
M. pneumoniae are small in most trials (Block 1995; Kogan 2003;
Wubbel 1999).
Identification of M. pneumoniae infection as the causative infec-
tious agent may, however, pose difficulties. Serological tests are
the most common method used to diagnose M. pneumoniae in-
fections, but can lead to difficulties with interpretation (Principi
2001). Measurement of immunoglobulin M (IgM) is used to di-
agnose acute infection, but the accuracy of the test depends on the
method used. Not all methods are specific for IgM and an elevated
IgM may persist for months after the acute infection (Murray
2003). Immuno-fluorescent antibody (IFA) assay is more sensi-
tive and specific than the complement fixation (CF) test (Murray
2003; Principi 2001). Identification ofM. pneumoniae in nasopha-
ryngeal secretions by culture or polymerase chain reaction (PCR)
may also cause difficulties with interpretation as this organism can
persist for variable periods following the acute infection (Murray
2003). The ’gold standard’ for diagnosis of M. pneumoniae infec-
tion is a four-fold increase in total antibody titre as measured in
paired sera (Katz 1998; Murray 2003).
O B J E C T I V E S
To determine whether antibiotics are effective in the treatment of
childhood LRTI secondary to M. pneumoniae infections acquired
in the community.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing antibiotics from the
macrolide, tetracycline or quinolone class versus placebo, or an-
tibiotics from any other class.
Types of participants
All trials that included children under 18 years of age with com-
munity acquired LRTI secondary to M. pneumoniae. Diagnosis
of M. pneumoniae infection was via either a four-fold rise in total
antibody titre from paired sera or total antibody titre ≥ 1:512 on
a single specimen. Other methods of diagnosis such as culture or
PCR of M. pneumoniae in nasopharyngeal secretions or demon-
stration of elevated IgM on a single specimen (IgM titre ≥ 1:10)
were included, and analysed separately as a subgroup
Exclusion criteria:
(a) children with underlying chronic cardiorespiratory illnesses
such as cystic fibrosis, bronchiectasis, immunodeficiency, chronic
neonatal lung disease and symptomatic congenital heart disease;
(b) children with non-community acquired LRTI.
Types of interventions
All randomised controlled trial (RCT) comparisons of antimicro-
bials from the macrolide, tetracycline or quinolone class, versus
placebo or other antibiotics in the management of LRTI.
Two separate treatment regimes were evaluated:
(a) any antibiotic versus placebo; and
(b) antibiotics from the macrolide, tetracycline or quinolone class
versus placebo, or antibiotics from any other class.
Trials that included the use of other medications or interventions
in addition to antibiotic therapy were included if all participants
had equal access to such medications or interventions.
Types of outcome measures
Attempts were made to obtain data on at least the following out-
come measures:
Primary outcomes
• proportions of participants who were not improved at
follow up. (Failure to improve will be measured according to the
hierarchy listed below ’secondary outcomes’.)
Secondary outcomes
• mean difference in symptoms and signs (mean
improvement in clinical state);
• proportions requiring hospitalisation;
• proportions experiencing pulmonary complications
(empyema, pleural effusion, air leak);
• proportions experiencing non-pulmonary complications;
• proportions experiencing adverse effects (for example
nausea, diarrhoea, abdominal pain, rash);
• proportions experiencing complications (for example
requirement for medication change).
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures. All outcomes were
reported but where two or more assessment measures are reported
in the same study and conflicting results are obtained, the outcome
measure that was listed first in the hierarchy was used.
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1. Objective measurements of cough indices (cough
frequency).
2. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well being, headache) - assessed by the child (Likert scale, visual
analogue scale, level of interference of symptoms, diary, quality
of life).
3. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well being, headache) - assessed by the parents/carers (Likert
scale, visual analogue scale, level of interference of symptoms,
diary, quality of life).
4. Symptomatic (cough, wheeze, dyspnoea, malaise, general
well being, headache) - assessed by the clinician (Likert scale,
visual analogue scale, level of interference of symptoms, diary,
quality of life).
5. Fever.
6. Non-clinical outcomes (chest radiology, white cell count, C-
reactive protein, erythrocyte sedimentation rate, lung function).
7. Eradication of M. pneumoniae by PCR evaluation.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2005, issue 1), which con-
tains the Acute Respiratory Infection Group’s Specialized Regis-
ter; MEDLINE (1966 to February 2005); and EMBASE (1980
to December 2004).
The following search terms were used for MEDLINE and CEN-
TRAL and adapted for EMBASE. The search terms used inMED-













11 respiratory tract infection$
12 acute respiratory infection$
13 or/5-12









22 (child or children)
23 (paediatric or pediatric)
24 or/21-23
25 4 and 13 and 20 and 24
There were no language restrictions.
Searching other resources
We checked all references for reports of trials.
Data collection and analysis
Selection of studies
Retrieval of studies: From the title, abstract or descriptions, we
independently reviewed literature searches to identify potentially
relevant trials for full review. Searches of bibliographies and texts
were conducted to identify additional studies. From the full text
using specific criteria, we independently selected trials for inclu-
sion. We measured agreement using the kappa statistic and re-
solved disagreement by consensus.
Data extraction and management
We independently extracted data and resolved disagreement by
consensus. Trials that satisfied the inclusion criteria were reviewed
and the following information recorded: study setting; year of
study; source of funding; patient recruitment details (including
number of eligible children); inclusion and exclusion criteria; ran-
domisation and allocation concealment method; numbers of par-
ticipants randomised; blinding (masking) of participants, care
providers and outcome assessors; intervention (type of anti-mi-
crobials, dose, duration); control (type, dose, duration); co-in-
terventions; numbers of patients not followed up; reasons for
withdrawals from study protocol (clinical, side-effects, refusal and
other); details on side-effects of therapy; andwhether intention-to-
treat analyses were possible. Data were extracted on the outcomes
described previously. We requested further information from the
study authors where required.
Assessment of risk of bias in included studies
We independently assessed the quality of studies included in the
review. Four components of quality were assessed:
1. Allocation concealment. Trials will be scored as: Grade A: Ad-
equate concealment; Grade B: Unclear; Grade C: Clearly inade-
quate concealment (Grade A = high quality).
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2. Blinding. Trials will be scored as: Grade A: Participant and
care provider and outcome assessor blinded; Grade B: Outcome
assessor blinded; Grade C: Unclear; Grade D: No blinding of
outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocation group. Trials will be
scored as: Grade A: The progress of all randomised children in each
group described; Grade B: Unclear or no mention of withdrawals
or dropouts; Grade C: The progress of all randomised children in
each group clearly not described (Grade A = high quality).
4. Follow up. Trials will be scored as: Grade A: Outcomes mea-
sured in more than 90% (where withdrawals due to complications
and side-effects are categorised as treatment failures); Grade B:
Outcomes measured in 80 to 90%; Grade C: Unclear; Grade D:
Outcomes measured in less than 80% (Grade A = high quality).
While only the allocation concealment quality is displayed in the
meta-analysis figures, all assessments were included in the table
’Characteristics of included studies’. Inter-author reliability for
the identification of high quality studies for each component was
measured by the kappa statistic.
Each study was assessed using a one to five scale described by Jadad
(Jadad 1996) and summarised as follows:
• Was the study described as randomised? (1 = yes; 0 = no)
• Was the study described as double blind? (1 = yes; 0 = no)
• Was there a description of withdrawals and dropouts? (1=
yes; 0 = no)
• Was the method of randomisation clearly described and
appropriate? (1= yes; 0 = no)
• Was the method of double blinding well described and
appropriate? (1= yes; 0 = no)
Unit of analysis issues
In the protocol it was planned to calculate relative and absolute
risk reductions using an intention-to-treat analysis for the dichoto-
mous outcome variables of each individual study. However, data
were unavailable.
In the protocol it was planned to include the results from studies
that met the inclusion criteria and report any of the outcomes of
interest in the subsequent meta-analysis. It was planned to cal-
culate the summary weighted risk ratio and 95% confidence in-
terval (CI) (fixed effect model) using the inverse of the variance
of each study result for weighting (Cochrane statistical package,
Review Manager 4.2). It was planned to calculate the number -
needed -to treat using the summary odds ratio and the average
control event rate described in the relevant studies. It was stated in
the protocol that the cough indicies were assumed to be normally
distributed continuous variables so the mean difference in out-
comes could be estimated (weighted mean difference). In studies
that reported outcomes using different measurement scales, the
standardised mean difference would be estimated. However, data
were unavailable.
In the protocol it was planned to describe any heterogeneity be-
tween the study results and, depending upon the number of trials
included in the review, a funnel plot was planned to look for pub-
lication bias. However, data were unavailable and no studies were
included in a meta-analysis.
In the protocol it was intended to perform an a priori subgroup
analysis for:
1. children aged seven years and older;
2. intervention type (class of antibiotics);
3. diagnostic criteria used for identification of M. pneumoniae.
However, data were unavailable.
In the protocol a sensitivity analyses was planned to assess the
impact of the potentially important factors on overall outcomes:
1. study quality;
2. study size;
3. variation in the inclusion criteria;
4. differences in the medications used and duration of
treatment in the intervention and comparison groups;
5. differences in outcome measures;
6. analysis by ’treatment received’ rather than ’intention-to
treat’.
However, data were unavailable.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The initial search identified 91 potentially relevant titles. After re-
viewing the abstracts, 17 papers in full text were obtained for con-
sideration of inclusion into the review. Ten papers were excluded
and details are provided in the table ’Characteristics of excluded
studies’. The main reasons for exclusion were the non-randomised
nature of the study (Jensen 1967; Sakata 2001;Vasilos 1995) or use
of inadequate placebo or comparator (Block 1995; Chien 1993;
Jensen 1967; Manfredi 1992; Nogeova 1997; Ronchetti 1994;
Schonwald 1990; Yin 2002). Three of the excluded studies were
non-English - Japanese (Sakata 2001), Russian (Vasilos 1995) and
Chinese (Yin 2002). Seven studies were included and details are
provided in the table ’Characteristics of included studies’. Three
of the included studies were non-English - German (Ruhrmann
1982) and Spanish (Gomez Campdera 1996; Saez-Llorens 1998).
Included studies
Participants
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The studies involved children diagnosed with LRTI ranging in
age from 1 month to 16 years. In all except two studies (Gomez
Campdera 1996; Soderstrom 1991) children had pneumonia sup-
ported with abnormal chest x-ray and apart from the study by
Ruhrmann 1982 the childrenwere described as having community
acquired pneumonia. The study by Gomez Campdera 1996 did
not define pneumonia and the study by Soderstrom 1991 included
patients with acute bronchitis. The number of children with M.
pneumoniae was not stated in three studies (Gomez Campdera
1996;Ruhrmann 1982; Saez-Llorens 1998). In one study (Wubbel
1999) there were 12 children with M. pneumoniae infections and
6 were in the subgroup randomised to either azithromycin or
amoxycillin-clavulanate, but the number assigned to each therapy
was not available. In two other studies the number of children
with M. pneumoniae infections in each intervention group was
provided - in the study byHarris 1998 there were 30 children who
had M. pneumoniae infections randomised to either azithromycin
or amoxycillin-clavulanate (21 in azithromycin group and 9 in
amoxycillin-clavulanate group), and there were eight children in
the study by Kogan 2003 (five in azithromycin group and three in
amoxycillin-clavulanate group). In the study by Soderstrom 1991
there were only seven patients with lower respiratory tract infec-
tions (bronchitis) and one case of M. pneumoniae, but the age of
the patient with M. pneumoniae was not provided.
Interventions
Studies included in this review involved patients with LRTI ran-
domised to either a macrolide antibiotic or another antibiotic,
usually a different macrolide or non-macrolide antibiotic. In two
studies (Ruhrmann 1982; Soderstrom 1991) the entire study pop-
ulation was randomised to either a macrolide or non-macrolide
antibiotic. Ruhrmann 1982 included children with pneumonia
who received either erythromycin 70 to 80 mg/kg/day or amoxy-
cillin 60 to 70 mg/kg/day. The duration of therapy was not stated.
The study by Soderstrom 1991 had a subgroup of patients (num-
ber of children not stated) with acute bronchitis who received
either erythromycin 500 mg twice daily for seven days or phe-
noxymethylpenicillin 800 mg twice daily for seven days. Four
studies (GomezCampdera 1996;Harris 1998; Saez-Llorens 1998;
Wubbel 1999) randomised a subgroup of children under five years
of age to azithromycin or amoxycillin-clavulanate. The dose of
amoxycillin-clavulanate was 40 mg/kd/day in three divided doses
for 10 days in all studies. The dose of azithromycin was 10 mg/kg
once daily for three days in one study (Gomez Campdera 1996)
and 10 mg/kg on day 1 followed by 5 mg/kg once daily for day
2 to 5 in three studies (Harris 1998; Saez-Llorens 1998; Wubbel
1999). In the study by Kogan 2003 the intervention for the sub-
group with classic pneumonia was either azithromycin 10 mg/kg
once daily for three days or amoxycillin 75 mg/kg/day in three
divided doses for seven days.
Outcomes
Clinical response was the main outcome but was not defined
in three studies (Gomez Campdera 1996; Ruhrmann 1982;
Soderstrom 1991). In three studies clinical cure was defined as
complete resolution of symptoms and signs by day 15 to 19 (Harris
1998), day 10 to 25 (Saez-Llorens 1998) and day 10 to 37 (Wubbel
1999). In the study by Kogan 2003 the clinical response was de-
fined as the proportion of children without fever on day 3. Radio-
logical outcome was recorded in three studies (Gomez Campdera
1996; Harris 1998; Kogan 2003) but was not defined in the study
byGomez Campdera 1996. Bacteriological outcome was recorded
in two studies (Harris 1998; Saez-Llorens 1998) but was not de-
fined in the study by Saez-Llorens 1998. Adverse events were
recorded by four studies (Gomez Campdera 1996; Harris 1998;
Saez-Llorens 1998; Wubbel 1999) and were only defined in the
study by Harris 1998.
Attempts were made to obtain individual patient data from three
studies (Harris 1998; Kogan 2003;Wubbel 1999) where the num-
ber of children with M. pneumoniae was identified, but no reply
was received at the time this review was completed.
Risk of bias in included studies
Jadad scores ranged from 1 to 3, with one study scoring 1 (Gomez
Campdera 1996), five studies scoring 2 (Harris 1998; Kogan
2003; Ruhrmann 1982; Saez-Llorens 1998; Wubbel 1999) and
one study scoring 3 (Soderstrom 1991). Agreement between the
two authors for quality of studies varied with weighted kappa
score of 0.18 for Jadad score and 0.49 for quality assessment. A
discussion between reviewers on how to interpret the Jadad scoring
system did not take place beforehand and this, along with the
small numbers involved, was reflected in the low kappa score. The
maindiscrepancy in quality assessment arosewith interpretation of
allocation concealment and reporting of participants by allocated
group. Disagreement in both instances was resolved by consensus.
Randomisation
All studies were described as randomised and the method of ran-
domisation was clearly described and appropriate in two studies
(Ruhrmann 1982; Saez-Llorens 1998) where a random number
list was used. The method of randomisation was unclear in one
study (Wubbel 1999) where themethod usedwas described as a list
of randomised therapy assignments. In the study by Soderstrom
1991 the method used was sequential patient numbers and this
was thought to be inadequate. Three studies (Gomez Campdera
1996; Harris 1998; Kogan 2003) did not describe the method of
randomisation.
Allocation
Concealment of allocation was unclear in all except two studies
(Saez-Llorens 1998; Wubbel 1999), where therapy was assigned
by pharmacy.
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Blinding
There was no blinding in four studies (Gomez Campdera 1996;
Ruhrmann 1982; Saez-Llorens 1998; Wubbel 1999). In the re-
maining three studies the blinding involved only the participant
(Harris 1998), clinician (Kogan 2003) or radiologist (Soderstrom
1991).
Effects of interventions
There were 1352 children enrolled from six studies. The number
of children from one study (Soderstrom 1991) was unavailable.
Data interpretation was significantly limited by the inability to ex-
tract data that specifically referred to childrenwithM. pneumoniae.
There were no studies of children randomised to any antibiotic
versus placebo. The included studies comprised a subgroup of chil-
dren who were randomised to a macrolide versus non-macrolide
antibiotic. The total number of children in this subgroup was not
known as the numbers were only available in four studies (Harris
1998; Kogan 2003; Ruhrmann 1982; Wubbel 1999). The num-
ber of children with LRTI secondary to M. pneumoniae in this
subgroup was only available in two studies (Harris 1998; Kogan
2003) and the lack of individual patient data did not allow for
inclusion of results in a meta-analysis. There was a total of 26 in
azithromycin group and 12 in amoxycillin-clavulanate group.
In the study by Gomez Campdera 1996 the rate of clinical cure
was 95.12% in the azithromycin group and 90.41% in the amoxy-
cillin-clavulanate group. Radiological improvement was noted in
90.6% of the azithromycin group. Adverse events were recorded
in 11.25% of the azithromycin group and 17.14% in the amoxy-
cillin-clavulanate group. Harris 1998 reported no difference in the
rate of clinical cure at day 15 to 19 (67.2% versus 66.7%) and
four to six weeks (85.1% versus 85.4%) of children randomised
to azithromycin or amoxycillin-clavulanate. M. pneumoniae was
identified in 16% (30 of 188 children under five years of age).
Eradication of M. pneumoniae occurred in three out of three in the
azithromycin group and in none out of one in the amoxycillin-
clavulanate group. Adverse events in those childrenunder five years
of age were 12.1% in the azithromycin group and 42.3% in the
amoxycillin-clavulanate group. One patient in each group discon-
tinued treatment because of adverse events. In the study by Kogan
2003 which compared azithromycin to amoxicillin in children
with classical pneumonia (8 children of 47 hadM. pneumoniae), x-
ray resolution was significantly better in those treated with azithro-
mycin (81% versus 60.9% at day 7) but there was no difference in
clinical symptoms or signs between groups. In those with atypical
pneumonia (23 children of 59 had M. pneumoniae) there was no
significant difference between children treated with azithromycin
or erythromycin (Kogan 2003). Ruhrmann 1982 reported clini-
cal cure after 3.79 days in erythromycin group and 3.96 days in
amoxycillin group. Saez-Llorens 1998 reported a similar clinical
response (99% versus 98%) in children under five years who were
randomised to azithromycin or amoxycillin-clavulanate. Eradica-
tion of M. pneumoniae occurred in 23 out of 24 in the azithro-
mycin group. Adverse events were reported in 11% on azithromy-
cin, 30% on amoxycillin-clavulanate and 27% on erythromycin.
Soderstrom 1991 did not report the clinical response in the sub-
group of patients with bronchitis. In the study by Wubbel 1999,
where 7% (12 of 168 children) had M. pneumoniae, no difference
was found in children randomised to azithromycin or amoxicillin-
clavulanate. Adverse events were reported in 14% on azithromy-
cin, 67% on amoxycillin-clavulanate and 25% on erythromycin.
Eleven patients did not complete the prescribed therapy.
D I S C U S S I O N
Summary of main results
This review failed to find any randomised controlled trials which
specifically looked at the effectiveness of antibiotics for LRTI sec-
ondary to M. pneumoniae. There were no studies of antibiotics
versus placebo. In the subgroup of children with LRTI secondary
to M. pneumoniae the intervention was a macrolide antibiotic ver-
sus a non-macrolide antibiotic, usually amoxycillin-clavulanate.
This subgroup identified only 38 children with M. pneumoniae
infection and there were insufficient data to analyse the efficacy
of macrolide antibiotics in this group. Adverse events were com-
mon, reported in 11% to 67%of children. Themajority of adverse
events related to the gastrointestinal tract (diarrhoea, vomiting,
abdominal pain, nausea, anorexia) and where reported, were more
common in younger children (under five years of age).
Quality of the evidence
Therewere significant difficulties in interpretationof data from the
included studies. Firstly, although all studies (except Soderstrom
1991) enrolled children with LRTI, only a proportion had M.
pneumoniae infection. It was not possible to obtain information
on the sub-group with M. pneumoniae. Secondly, the dose and
type of antibiotics differed among studies. Thirdly, application
of diagnostic criteria (serology versus PCR) varied and these are
not necessarily interchangeable. Fourthly, the inclusion criteria
differed (various types of LRTI manifestation) between studies.
Furthermore the outcomes measured were variable and in some
papers, clinical cure was undefined.
Despite the commonality of M. pneumoniae LRTI in children (up
to 40% of CAP reported by Waites 2003), there is surprisingly
no RCT that has specifically evaluated the efficacy of antibiotics
for the treatment of childhood LRTI secondary to M. pneumoniae
infections acquired in the community. This is reflected in conflict-
ing advice given in paediatric textbooks (Phelan 1994; Rudolph
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2003) and this systematic review has highlighted the need for such
studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found insufficient evidence to draw any conclusions
about the efficacy of antibiotics for LRTI secondary toM. pneumo-
niae in children. The use of antibiotics for M. pneumoniae LRTI
has to be individualised depending on the clinical context (for ex-
ample setting, clinical history and signs, presence of immunode-
ficiency etc) and balanced with possible adverse events associated
with antibiotic use.
Implications for research
M. pneumoniae infection is relatively commonand its clinicalman-
ifestations range from being asymptomatic to death from com-
plications of M. pneumoniae infection. As respiratory symptoms
are the most common symptoms, there is a need for high quality,
double-blinded randomised controlled trials to assess the efficacy
and safety of antibiotics for LRTI secondary to M. pneumoniae
in children. Studies should consider the various clinical and mi-
crobiological diagnostic criteria of M. pneumoniae infection and
utilise clear outcome criteria. Community studies using PCR for
rapid early diagnosis would be valuable to evaluate the efficacy of
antibiotics for M. pneumoniae for respiratory and non respiratory
manifestations as well as for prevention of complications and mi-
crobiological clearance of M. pneumoniae.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gomez Campdera 1996
Methods Patients were recruited from emergency department with a diagnosis of pneumonia for the periods 1
May 1994 to 30 April 1995 and 1 December 1995 to 30 June 1996. Inclusion and exclusion criteria
were not stated. Study participants were randomised to azithromycin or either amoxycillin-clavulanate if
under 5 years and erythromycin if over 5 years. The method of randomisation was not described. The
study was not blinded. There was no description of withdrawals or dropouts. There was no assessment of
compliance. Clinical outcomes were evaluated on day 3, 10 and 30, and chest x-ray was repeated on day
30. Outcomes measures included clinical response, hospitalisation, radiological improvement and adverse
events. Clinical response was classified as unchanged, improved, cured or worse. These categories were
not defined. Radiological improvement at day 30 was not defined
Assessment of Quality
1. Allocation concealment: Grade B
2. Blinding: Grade D
3. Reporting of participants by allocation group: Grade B
4. Follow up: Grade C
Jadad Score: 1
Participants 155 children aged 6 months to 16 years with pneumonia. Males = 84. Number of children with M.
pneumoniae infection in each group not stated
Interventions Group A (n = 82): azithromycin 10 mg/kg/day OD for 3 days.
Group B (n = 73): amoxycillin-clavulanate 40 mg/kg/day TID for 10 days if under 5 years and ery-






Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Harris 1998
Methods Patients were recruited from 23 centres with a diagnosis of community acquired pneumonia from 31
January 1994 to 31May 1995. Inclusion criteria were children with clinically suspected pneumonia based
on a radiological finding and the presence of tachyapnoea. In addition patients had at least one of the
following: fever or history of fever within 24 hours, cough, WCC >= 12000/mm, or chest findings sug-
gestive of pneumonia. Exclusion criteria were hypersensitivity to macrolides, penicillin or beta-lactam an-
tibiotics, pregnancy or lactation, parenteral therapy required because of severe or multilobar pneumonia,
treatment with any other systemic antibiotics within enrolment, evidence of underlying haematological,
renal, hepatic or cardiovascular disease, chronic steroid use or concomitant treatment with theophylline,
carbamazine, ergotamine, digitalis glycosides, terfenadine, loratadine or astemizole. Study was a multi-
centre, parallel group in which participants were randomised 2:1 to azithromycin or either amoxycillin-
clavulanate if under 5 years and erythromycin if over 5 years. The method of randomisation was not
described. Participants were blinded to therapy but there was no mention of blinding of clinicians or
outcome assessors. There was a description of withdrawals or dropouts. There was an assessment of com-
pliance by comparing medication bottle weights at beginning and end of study. Patients were evaluated
at four clinic visits: baseline; study days 2 to 5; study days 15-19; and 4-6 weeks post therapy. Laboratory
tests were obtained at baseline and on Study days 15-19. Chest x-rays were obtained at baseline and
4-6 weeks post-therapy. Evidence of infection with M. pneumoniae was determined by enzyme-linked
immunosorbent assay and defined as either single positive serum IgM (>= 1:10) or 4-fold increase in
IgG titre. Clinical response at study days 15 to 19 was classified as: cure, complete resolution of signs
and symptoms of pneumonia; improvement, incomplete resolution of signs and symptoms of pneumo-
nia; failure, persistence (or progression) of signs and symptoms of pneumonia after 3 days of therapy or
development of new clinical findings consistent with active infection or persistence (or progression) of
radiological findings obtained when clinically indicated. Clinical response 4 to 6 weeks post-therapy was
classified as follows: cure; complete resolution of signs and symptoms of pneumonia and improvement or
resolution of radiographic findings; failure; persistence (or progression) of signs and symptoms of pneu-
monia after 3 days of therapy or development of new clinical findings consistent with active infection
or persistence (or progression) of radiological findings. Bacteriological response was classified as follows:
eradication (presumed or proven), elimination of the original organism from the same site during or
after completion of therapy and includes cases where repeat specimens were nor obtained and patients
considered a clinical cure or improved; persistence, failure to eradicate the organism and includes cases
where specimens were not obtainable at the time alternative therapy was instituted and the patient was
considered a clinical failure. Adverse events were monitered throughout the study by reported symptoms,
physical examinations and laboratory tests. Events were rated by severity (mild, moderate or severe at the
discretion of the investigator), organ system and relation to study drug
Assessment of Quality
1. Allocation concealment: Grade B
2. Blinding: Grade C
3. Reporting of participants by allocation group: Grade A
4. Follow up: Grade B
Jadad Score: 2
Participants 456 children aged 6 months to 15 years with CAP were enrolled. 36 patients (25 in azithromycin group
and 11 in comparator group) were excluded for methodologic reasons leaving 420 patients (285 in
azithromycin and 135 in comparator group) available for analysis. Six children discontinued treatment
because of adverse events. Males = 236. The number of children with M. pneumoniae in the group
randomised to macrolide versus non-macrolide (i.e. children < 5 years) was 30 with 21 in azithromycin
group and 9 in amoxycillin-clavanulate group
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Harris 1998 (Continued)
Interventions Children under 5 years only -
Group A (n = 125): azithromycin 10 mg/kg OD day 1, 5 mg/kg OD day 2 to 5, and placebo day 1 to
10.







Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Kogan 2003
Methods Patients with a diagnosis of community acquired pneumonia were recruited from 1 January 1996 to
1 January 1999. Inclusion criteria were children with a clinical diagnosis radiologically confirmed of
presumed bacterial community acquired pneumonia, eligible for treatment with oral antibiotics and
without signs of respiratory insufficiency. Exclusion criteria were history or evidence of chronic pathology
of any organ system, chronic pulmonary disease, history of prematurity, treatment with any antibiotics
within 5 days prior to enrolment, or known hypersensitivity to beta-lactam antibiotics or macrolides.
The study population was divided into two groups according to clinical and radiological patterns. One
group included those children who presented with signs of classic bacterial pneumonia, with high fever
and chest findings of crackles or signs of consolidation, and chest x-rays with segmental, alveolar, or
lobar consolidation. The second group included patients with atypical pneumonia, with prominent and
frequently paroxysmal cough, variable fever, few clinical signs of consolidation, crackles and wheezing, and
chest x-rays with amixed alveolar-interstitial pattern. Participants with classic pneumoniawere randomised
to either amoxycillin or azithromycin, whereas patients in the atypical pneumonia were randomly assigned
to either azithromycin or erythromycin. The method of randomisation was not described. There was
no mention of blinding except for blinding of the radiologist who viewed follow up chest x-rays done
on study days 7 and 14. There was a description of withdrawals or dropouts. There was no assessment
of compliance. Outcomes were evaluated at three clinic visits, on study days 3, 7 and 14. A chest x-
ray was done in each child on study days 7 and 14. Evidence of infection was determined by indirect
immunofluorescence (IFI) and enzyme-linked immunosorbent assay to test sera for IgM antibiodies to
M pneumoniae. An antibody titre > 1:16 on a single first serum specimen was considered positive for IFI.
Clinical Response in the classic pneumonia group was defined as proportion of children without fever on
day 3 and/or improvement of more than 75% of radiographic baseline findings on study day 7
Assessment of Quality
1. Allocation concealment: Grade B
2.Blinding: Grade C
3. Reporting of participants by allocation group: Grade A
4. Follow-up: Grade B
Jadad Score: 2
Participants 110 children aged 1 month to 14 years were enrolled. 4 children developed serious pneumonia in the first
12 hours of enrolment and were excluded from the study (3 from the atypical group and 1 from the classic
group). The remaining 106 completed the study. The mean age was 4.9 years and 53 were male. 47 met
the criteria for classic pneumonia. The number of children with M. pneumoniae in the classic group was
8, with 5 in azithromycin group and 3 in amoxycillin-clavanulate group
Interventions Patients with classic pneumonia:
Group A (n = 23): azithromycin 10 mg/kg OD for 3 days.
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Ruhrmann 1982
Methods Patients were recruited from emergency departments in Dallas and Panama with a diagnosis of com-
munity acquired pneumonia for the period February 1996 to December 1997. Inclusion criteria were
tachyapnoea, fever, cough, crackles and CXR with changes compatible with pneumonia. Exclusion cri-
teria were hypersensitivity to macrolides or beta-lactam antibiotics, pregnancy, nosocomial pneumonia,
use of systemic antibiotics 72 hours prior to recruitment, chronic illness such as HIV, malignancy, cystic
fibrosis, haematologic, renal, cardiovascular, hepatic or pulmonary diseases, as well as patients on teofilin,
antihistamines, steroids or any medications with potential interaction with macrolides. Study participants
were randomised to azithromycin or either amoxycillin-clavulanate if under 5 years and erythromycin
if over 5 years. A random number list was used and therapy assigned by pharmacy. The study was not
blinded. There was a description of withdrawals or dropouts. There was no assessment of compliance.
Clinical outcomes were evaluated on day 2-3 and 10-25. Evidence of infection with M. pneumoniae was
defined as either single positive serum IgM (>1:16), 4-fold increase in IgG titre or positive PCR. Outcomes
measures included clinical response, hospitalisation, and eradication of M. pneumoniae. Clinical response
was classified as clinical cure or fail. Cure was defined as complete resolution or evident improvement of
all clinical symptoms and signs, and fail was defined as persistent or progression of symptoms after 3 days
of treatment. Eradication of M. pneumoniae was not defined
Assessment of Quality
1. Allocation concealment: Grade A
2. Blinding: Grade D
3. Reporting of participants by allocation group: Grade B
4. Follow up: Grade C
Jadad Score: 2
Participants 120 children aged 6 months to 14 years with pneumonia. Gender ratio not stated. Number of children
with M. pneumoniae infection in each group not stated
Interventions Group A: erythromycin 70 to 80 mg/kg/day. Duration of therapy not stated.
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Saez-Llorens 1998
Methods Patients were recruited from emergency departments in Dallas and Panama with a diagnosis of com-
munity acquired pneumonia for the period February 1996 to December 1997. Inclusion criteria were
tachyapnoea, fever, cough, crackles and CXR with changes compatible with pneumonia. Exclusion cri-
teria were hypersensitivity to macrolides or beta-lactam antibiotics, pregnancy, nosocomial pneumonia,
use of systemic antibiotics 72 hours prior to recruitment, chronic illness such as HIV, malignancy, cystic
fibrosis, haematologic, renal, cardiovascular, hepatic or pulmonary diseases, as well as patients on teofilin,
antihistamines, steroids or any medications with potential interaction with macrolides. Study participants
were randomised to azithromycin or either amoxycillin-clavulanate if under 5 years and erythromycin
if over 5 years. A random number list was used and therapy assigned by pharmacy. The study was not
blinded. There was a description of withdrawals or dropouts. There was no assessment of compliance.
Clinical outcomes were evaluated on day 2-3 and 10-25
Clinical outcomes were evaluated on Group A: erythromycin 70 to 80 mg/kg/day. Duration of therapy
not stated.
Group B: amoxycillin 60 to 70 mg/kg/day. Duration of therapy not stated.day 2-3 and 10-25. Evidence of
infection with M. pneumoniae was defined as either single positive serum IgM (>1:16), 4-fold increase in
IgG titre or positive PCR. Outcomes measures included clinical response, hospitalisation, and eradication
of M. pneumoniae. Clinical response was classified as clinical cure or fail. Cure was defined as complete
resolution or evident improvement of all clinical symptoms and signs, and fail was defined as persistent
or progression of symptoms after 3 days of treatment. Eradication of M. pneumoniae was not defined
Assessment of Quality
1. Allocation concealment: Grade A
2. Blinding: Grade D
3. Reporting of participants by allocation group: Grade B
4. Follow up: Grade C
Jadad Score: 2
Participants Total of 335 children aged 6 months to 15 years with CAP - 168 from Dallas with 106 under 5 years
(males = 92) and 167 from Panama with 142 under 5 years (males = 98). Thirty-nine children dropped
out. Number of children with M. pneumoniae infection in each group not stated
Interventions Group A: azithromycin 10 mg/kg on day 1 and 5mg/kg OD for days 2 to 5.
Group B: amoxycillin-clavulanate 40 mg/kg/day TID for 10 days if under 5 years and erythromycin 40
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Soderstrom 1991
Methods Patients aged > 10 years were recruited with any of the following diagnoses: sinusitis, tonsillitis, purulent
nasopharyngitis or bronchitis. Inclusion criteria defined acute bronchitis by the presence of at least 4 of
the following 5 criteria: (a) cough; (b) increased amounts of sputum; (c) rhonchus; (d) leucocytosis (> 10 x
10 9 leucocytes/l); and (e) temperature > 38 degrees C. Exclusion criteria were allergies to erythromycin or
penicillin, those treated with steroids, theophylline or antibiotics within 10 days preceding consultation.
The patients in each diagnosis group were randomly assigned to treatment with erythromycin capsules
or phenoxymethylpenicillin tablets. The patients were given sequential patient numbers, which indicated
which of the two treatments should be given to each patient. The physician at the first visit and the
nurse who met the patient at follow up visits were blinded to the intervention. There is no mention of
whether the patient was blinded to intervention. There was a description of withdrawals or dropouts.
Compliance was assessed by analysing urine sample collected during treatment (days 3-7). The patients
kept a daily record of symptoms and were reviewed by nurse 10 to 12 days after their initial visit. Evidence
of M. pneumoniae infection was made on the basis of four-fold rise in antibody titre. Outcome measures
included clinical response and adverse reactions. Clinical response was classified as asymptomatic, minor
symptoms, Streptococcal relapse/re-infection and treatment failure. These clinical outcomes were not
defined
Assessment of Quality
1. Allocation concealment: Grade B
2. Blinding: Grade B
3. Reporting of participants by allocation group: Grade A
4. Follow up: Grade A
Jadad Score: 3
Participants 138 patients were recruited with age range 10 to 70 years (median 32.5). Males = 56. Two patients
dropped out. There were only 7 with bronchitis (lower respiratory tract infection) and M. pneumoniae
was identified in 1 case
Interventions Group A: erythromycin 500 mg twice daily for 7 days.
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Wubbel 1999
Methods Patients were recruited from emergency clinic Children’s Medical Centre Dallas, Texas with a diagnosis of
community acquired pneumonia from February 1996 to December 1997. Inclusion criteria were children
with tachypnoea, fever, cough or rales and an abnormal chest x-ray consistent with pneumonia and con-
sidered to have community acquired infection. Exclusion criteria were hypersensitivity to macrolides or
beta-lactam antibiotics, pregnancy or lactation, nosocomial acquired infections, hospitalisation, systemic
antibiotic within 72 hours before enrollment, cefixime or ceftriaxone within the previous 7 days and
chronic diseases. Patients were also excluded if they were receiving medications that had potential adverse
interactions with erythromycin or azithromycin. Study participants were randomised to azithromycin or
either amoxycillin-clavulanate if under 5 years and erythromycin if over 5 years. A list of randomised
therapy assignments was used by research pharmacist to provide patients with either azithromycin, amoxy-
cillin-clavulanate or erythromycin. There was no mention of blinding of participants, clinicians or out-
come assessors except radiologists who reviewed all radiographs and were not familiar with the patient’s
clinical history or results of special studies. There was a description of withdrawals or dropouts. There
was an assessment of compliance by measuring the volume of drug in the bottle at 2 to 5 week visit.
Clinical evaluation occurred at enrolment, 2 to 3 days and 10 to 37 days after start of therapy. At day 2
to 3 a telephone call was made to the caregiver to assess symptoms, interventions and adverse reactions.
Patients were assessed at Weeks 2 to 5 for symptoms, adverse reactions and outcome. At this assessment
bacteriological samples were collected - nasopharyngeal and pharyngeal swabs for culture and PCR and
serum for convalescent antibody titres. A chest x-ray was repeated only if a patient had signs of persistent or
new infection. Clinical response was defined as: cure, resolution of all signs and symptoms; improvement,
incomplete resolution of all signs and symptoms; and failure, persistence or progression after 3 days of
therapy, new clinical findings suggesting active infection or death related to pneumonia. Bacteriological
response was not defined. Adverse events were monitored throughout the study. Evidence of infection
with M. pneumoniae was determined by serology (enzyme-linked immunosorbent assay), and culture or
PCR from nasopharyngeal swabs. Positive serology was defined as either single positive serum IgM (>= 1:
10) or 4-fold increase in IgG titre
Assessment of Quality
1. Allocation concealment: Grade A
2. Blinding: Grade D
3. Reporting of participants by allocation group: Grade A
4. Follow up: Grade B
Jadad Score: 2
Participants 174 children aged 6 months to 16 years with CAP were enrolled. Six patients were excluded because of
normal chest x-rays. Twenty-one children were excluded from clinical evaluation; 10 failed to return for
follow up examination and 11 did not complete treatment. Gender ratio was not mentioned. The total
number of children with M. pneumoniae was 12. However, it was not possible to determine how many
children with M. pneumoniae were in the group < 5 years who were randomised to either azithromycin
or amoxycillin-clavulanate because of lack of individual patient data
Interventions Children under 5 years only -
Group A (n = 39): azithromycin 10 mg/kg OD day 1, followed by 5 mg/kg OD day 2 to 5.
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Wubbel 1999 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
n = number
OD = daily
TID = three times a day
CXR = chest x-ray
PCR = polymerase chain reaction
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Block 1995 Inappropriate intervention. Comparison between two drugs from macrolide group - clarithromycin versus ery-
thromycin ethylsuccinate
Chien 1993 Inappropriate intervention. Comparison between two drugs from macrolide group - clarithromycin versus ery-
thromycin
Jensen 1967 Inappropriate intervention and study not randomised. Study looked at treatment of all affected individuals with
oxytetracycline and there was no placebo group. Household contacts were treated with either oxytetracycline or
placebo to determine effectiveness of oxytetracycline in secondary prevention ofmycoplasma infections. Allocation
of treatment of household contacts was not randomised
Manfredi 1992 Inappropriate intervention. Comparison between two drugs from macrolide group - azithromycin versus ery-
thromycin
Nogeova 1997 Inappropriate intervention. Comparison between two drugs from cephalosporin group - ceftibuten versus ce-
furoxime-axetil
Ronchetti 1994 Inappropriate intervention. Comparison between two drugs from macrolide group - azithromycin versus
josamycin
Sakata 2001 Study participants were not randomised.
Schonwald 1990 Inappropriate intervention. Comparison between two drugs from macrolide group - azithromycin versus ery-
thromycin
Vasilos 1995 Study participants were not randomised.
Yin 2002 Inappropriate intervention. Comparison between two drugs from macrolide group - oral azithromycin versus
intravenous erythromycin
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 20 May 2005.
Date Event Description
22 July 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 3, 2005
C O N T R I B U T I O N S O F A U T H O R S
JG wrote the protocol, independently selected papers for inclusion, assessed quality and extracted data, and wrote review.
AC edited and co-wrote protocol, independently selected papers for inclusion, assessed quality and extracted data, and edited and co-
wrote review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• West Moreton Health Service District, Ipswich, Australia.
• Royal Children’s Hospital, Brisbane, Australia.
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External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Mycoplasma pneumoniae; Anti-Bacterial Agents [∗therapeutic use]; Bronchitis [∗drug therapy; microbiology]; Community-Acquired
Infections [drug therapy; microbiology]; Pneumonia, Mycoplasma [∗drug therapy]
MeSH check words
Child; Humans
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